CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and CureVac (NASDAQ:CVAC – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Risk & Volatility
CRISPR Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.
Insider and Institutional Ownership
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 2.1% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics | -3,368.72% | -24.39% | -18.25% |
| CureVac | 199.92% | -23.03% | -19.09% |
Valuation and Earnings
This table compares CRISPR Therapeutics and CureVac”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics | $3.51 million | 1,579.27 | -$581.60 million | ($4.76) | -12.04 |
| CureVac | $70.74 million | 14.78 | $175.50 million | $0.72 | 6.47 |
CureVac has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for CRISPR Therapeutics and CureVac, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CRISPR Therapeutics | 1 | 6 | 9 | 1 | 2.59 |
| CureVac | 1 | 0 | 0 | 0 | 1.00 |
CRISPR Therapeutics currently has a consensus target price of $67.94, suggesting a potential upside of 18.51%. Given CRISPR Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe CRISPR Therapeutics is more favorable than CureVac.
Summary
CRISPR Therapeutics beats CureVac on 8 of the 15 factors compared between the two stocks.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
